---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-063347"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:17:54.982561+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Larimar completes Phase 2 50mg cohort enrollment; top-line data now Q1 2024; cash to Q1 2025

## Summary
- Completed enrollment and dosing of 50 mg cohort in Phase 2 FA trial; no serious adverse events observed (blinded).
- Top-line safety, PK, and frataxin data now expected in Q1 2024, refined from H1 2024.
- Open-label extension trial with 25 mg daily nomlabofusp on track for Q1 2024; interim data expected Q4 2024.
- Cash, equivalents, and marketable securities of $95.6M as of Sep 30, 2023; projected runway into Q1 2025.
- Q3 2023 net loss $9.1M ($0.21/share) vs $8.3M ($0.37/share) in Q3 2022; R&D expenses up to $6.6M.

## SEC filing metadata
- accession: 0000950170-23-063347
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000095017023063347/0000950170-23-063347-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000095017023063347/lrmr-20231113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-063347
- JSON: https://secwatch.observer/filing/0000950170-23-063347.json
- Plain text: https://secwatch.observer/filing/0000950170-23-063347.txt

## Key facts
- Earnings Releases
  Larimar Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income net loss of $9.1 million, or $0.21 per share, EPS ($0.21) per share.
  - Period: third quarter ended September 30, 2023
  - Net income: net loss of $9.1 million, or $0.21 per share
  - EPS: ($0.21) per share
  - Result: reported results
  source text: Larimar Therapeutics, Inc. (the " Company ") announced its financial results and operational highlights for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374690/000095017023063347/0000950170-23-063347-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.